TNXP | tickerfilter.com

Fundamental analysis

21%

Profitability 25%

Dept financing 4%

Liquidity 50%

Performance 15%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-3.52%

1 Month

-17.23%

3 Months

-32.38%

6 Months

-46.82%

1 Year

-0.15%

2 Year

12.27%

Key data

Stock price

$13.45

P/E Ratio

0.00

DAY RANGE

$13.07 - $13.72

EPS

-$40.31

52 WEEK RANGE

$12.35 - $69.97

52 WEEK CHANGE

-$0.15

MARKET CAP

211.784 M

YIELD

N/A

SHARES OUTSTANDING

11.777 M

DIVIDEND

$0.00

EX-DIVIDEND DATE

02-05-2025

NEXT EARNINGS DATE

05-12-2025

BETA

0.20

PUBLIC FLOAT

AVERAGE 10 VOLUME

$345,226

AVERAGE 30 VOLUME

$321,422

Company detail

CEO: Seth Lederman
Region: US
Website: tonixpharma.com
Employees: 50
IPO year: 2012

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Tonix Pharmaceuticals Holding Corp. focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

TNXP - Tonix Pharmaceuticals Holding Corp.